Holen Sie sich die Stockscreener-App
13.80
5.48%
-0.80
Vorhandelsmarkt:
13.58
-0.22
-1.59%
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million - Investing.com
Fulcrum Therapeutics (FULC) Expands Offering to $175M - GuruFocus
Fulcrum Therapeutics prices $175 million public offering By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics Prices $175 Million Stock Offering - marketscreener.com
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Fulcrum Therapeutics announces pricing of upsized $175.0 million public offering of common stock and pre-funded warrants - marketscreener.com
Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - Benzinga
Fulcrum Therapeutics (Nasdaq: FULC) sets $13.50 price for 11,851,853-share equity sale - Stock Titan
B of A Securities Maintains Fulcrum Therapeutics (FULC) Underperform Recommendation - Nasdaq
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
FULC: Analyst Rating Maintained by B of A Securities, Price Targ - GuruFocus
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data - Yahoo Finance
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial - MSN
Fulcrum Therapeutics dips after unveiling $150 million share sale - TradingView
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
HC Wainwright & Co. Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Fulcrum Therapeutics (FULC) Launches $150M Public Stock Offering - GuruFocus
Fulcrum stock drops after announcing $150 million public offering By Investing.com - Investing.com Australia
Fulcrum Therapeutics launches $150 million common stock offering - Investing.com
Fulcrum stock drops after announcing $150 million public offering - Investing.com
Fulcrum Therapeutics launches $150 million common stock offering By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Launches $150 Million Common Stock Offering - marketscreener.com
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - The Manila Times
Fulcrum Therapeutics (Nasdaq: FULC) starts proposed $150.0M raise, plus $22.5M option - Stock Titan
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
BofA Securities raises Fulcrum Therapeutics stock price target on SCD drug data - Investing.com Canada
Fulcrum Therapeutics’ Promising Surge: Analyzing Recent Progress - StocksToTrade
The growth track for Fulcrum Therapeutics Inc (FULC) has changed recently - Setenews
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - inkl
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Stifel raises Fulcrum Therapeutics stock price target to $25 on strong ASH data - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Fulcrum Therapeutics jumps after trial data of blood disorder drug - TradingView
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
FULC: Cantor Fitzgerald Raises Price Target to $24, Maintains Ov - GuruFocus
FULC: RBC Capital Raises Price Target to $10, Maintains Sector P - GuruFocus
Piper Sandler Raises Price Target and Reiterates Overweight Rati - GuruFocus
Is Fulcrum Therapeutics Stock Set to Skyrocket? - timothysykes.com
Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data - Investing.com UK
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
FULC Stock Sees Analyst Rating Update from HC Wainwright | FULC - GuruFocus
Fulcrum Therapeutics stock price target raised to $23 from $16 at Piper Sandler - Investing.com UK
Why Fulcrum Therapeutics Stock Is Surging Nearly 50% Today? - Tokenist
RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk - marketscreener.com
Fulcrum Therapeutics stock price target raised to $25 from $18 at H.C. Wainwright - Investing.com UK
Fulcrum Therapeutics (FULC) Surges on Promising Trial Results - GuruFocus
Fulcrum Therapeutics Announces Initial Results from Phase 1b PIONEER Trial of Pociredir - TradingView
Fulcrum Stock Nears 2024 Highs: Early Stage Sickle-Cell Data Sparks Target Price Hikes - Stocktwits
Fulcrum Therapeutics stock price target raised to $10 from $7 at RBC Capital - Investing.com Canada
Fulcrum Therapeutics (FULC) Sees Promising Results in Sickle Cel - GuruFocus
Fulcrum reports positive results for sickle cell drug pociredir By Investing.com - Investing.com Canada
Fulcrum Therapeutics Reports Positive Initial Results from Phase 1b PIONEER Trial of Pociredir for Sickle Cell Disease - Quiver Quantitative
Fulcrum Therapeutics (Nasdaq: FULC) 20 mg pociredir sends 58% of SCD patients to ≥20% HbF at Week 6 - Stock Titan
Fulcrum Therapeutics (Nasdaq: FULC) issues options at $9.87 under 2022 inducement plan - Stock Titan
How strong is Fulcrum Therapeutics Inc. stock balance sheetTrade Volume Summary & Entry Point Confirmation Signals - Newser
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.7%Here's What Happened - MarketBeat
Will Fulcrum Therapeutics Inc. stock benefit from green energy trends2025 Top Decliners & Weekly Return Optimization Plans - Newser
A History of Outperforming Analyst Forecasts and Beating the Odds: Fulcrum Therapeutics Inc (FULC) - Setenews
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):